Phosphorylation of PBK/TOPK Tyr74 by JAK2 promotes Burkitt lymphoma tumor growth.

[1]  H. Mei,et al.  Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma , 2021, Haematologica.

[2]  Rathi Puliyadi,et al.  Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress , 2020, Cell Death & Differentiation.

[3]  Jung-hwan Park,et al.  Activation of NF-κB by TOPK upregulates Snail/Slug expression in TGF-β1 signaling to induce epithelial-mesenchymal transition and invasion of breast cancer cells. , 2020, Biochemical and biophysical research communications.

[4]  A. Noy.  Burkitt Lymphoma - Subtypes, Pathogenesis, and Treatment Strategies. , 2020, Clinical lymphoma, myeloma & leukemia.

[5]  Shuyi Chen,et al.  Status and prognostic nomogram of patients with Burkitt lymphoma , 2019, Oncology letters.

[6]  Hongbo Hu,et al.  Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells , 2019, Cell Death & Disease.

[7]  T. Kasama,et al.  TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation. , 2019, International journal of oncology.

[8]  L. mcauliffe,et al.  Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis , 2019, The Annals of pharmacotherapy.

[9]  Wen-Qi Jiang,et al.  Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis , 2019, Cancer medicine.

[10]  Zhengliang Ma,et al.  [Intrathecal injection of AG-490 reduces bone-cancer-induced spinal cord astrocyte reaction and thermal hyperalgesia in a mouse model]. , 2018, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[11]  Michael L. Wang,et al.  B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma. , 2018, Blood.

[12]  Giacomo Pirovano,et al.  T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics , 2018, Cell Death & Disease.

[13]  Min Liu,et al.  Inhibition of JAK2/STAT3 Signaling Pathway Suppresses Proliferation of Burkitt’s Lymphoma Raji Cells via Cell Cycle Progression, Apoptosis, and Oxidative Stress by Modulating HSP70 , 2018, Medical science monitor : international medical journal of experimental and clinical research.

[14]  Weiya Ma,et al.  Targeting PRPK Function Blocks Colon Cancer Metastasis , 2018, Molecular Cancer Therapeutics.

[15]  Wenhua Yu,et al.  P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling , 2018, Molecular and Cellular Biochemistry.

[16]  S. Kuroda,et al.  Targeting the T-Lak cell originated protein kinase by OTS964 shrinks the size of power-law coded heterogeneous glioma stem cell populations , 2017, Oncotarget.

[17]  M. Kersten,et al.  Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens , 2017, Annals of Hematology.

[18]  Lin-Li Li,et al.  A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models , 2017, Oncotarget.

[19]  D. Alberts,et al.  ADA-07 Suppresses Solar Ultraviolet–Induced Skin Carcinogenesis by Directly Inhibiting TOPK , 2017, Molecular Cancer Therapeutics.

[20]  F. Kang,et al.  IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro , 2017, Cellular Physiology and Biochemistry.

[21]  Ran Wei,et al.  microRNA-375 inhibits colorectal cancer cells proliferation by downregulating JAK2/STAT3 and MAP3K8/ERK signaling pathways , 2017, Oncotarget.

[22]  G. Salles,et al.  Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[23]  A. Ashworth,et al.  Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma* , 2016, The Journal of Biological Chemistry.

[24]  C. Shao,et al.  Phosphorylation of TOPK at Y74, Y272 by Src increases the stability of TOPK and promotes tumorigenesis of colon , 2016, Oncotarget.

[25]  T. Lu,et al.  Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase , 2016, Oncotarget.

[26]  T. Lu,et al.  PDZ-binding kinase/T-LAK cell-originated protein kinase is a target of the fucoidan from brown alga Fucus evanescens in the prevention of EGF-induced neoplastic cell transformation and colon cancer growth , 2016, Oncotarget.

[27]  Y. Li,et al.  TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun , 2016, Oncotarget.

[28]  T. Lu,et al.  TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer , 2015, Oncotarget.

[29]  Yusuke Nakamura,et al.  TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis , 2014, Science Translational Medicine.

[30]  L. Gordon,et al.  A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  S. Maddika,et al.  TOPK and PTEN participate in CHFR mediated mitotic checkpoint☆ , 2013, Cellular signalling.

[32]  E. Hill,et al.  Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. , 2012, Blood.

[33]  Yong-Yeon Cho,et al.  Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. , 2012, Cancer research.

[34]  C. Harrison,et al.  Burkitt's lymphoma , 2012, The Lancet.

[35]  Michael L. Wang,et al.  Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. , 2010, Blood.

[36]  Xiaoyong Li,et al.  PBK/TOPK expression during TPA-induced HL-60 leukemic cell differentiation. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[37]  Yong-Yeon Cho,et al.  T-LAK Cell-originated Protein Kinase (TOPK) Phosphorylation of MKP1 Protein Prevents Solar Ultraviolet Light-induced Inflammation through Inhibition of the p38 Protein Signaling Pathway* , 2011, The Journal of Biological Chemistry.

[38]  Ji-shuai Zhang,et al.  T-LAK Cell-originated Protein Kinase (TOPK) Phosphorylation of Prx1 at Ser-32 Prevents UVB-induced Apoptosis in RPMI7951 Melanoma Cells through the Regulation of Prx1 Peroxidase Activity* , 2010, The Journal of Biological Chemistry.

[39]  Yusuke Nakamura,et al.  Critical roles of T‐LAK cell‐originated protein kinase in cytokinesis , 2010, Cancer science.

[40]  C. Bellan,et al.  Burkitt lymphoma versus diffuse large B‐cell lymphoma: a practical approach , 2009, Hematological oncology.

[41]  Y. Abe,et al.  A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis. , 2007, Journal of molecular biology.

[42]  Weiya Ma,et al.  Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. , 2007, Gastroenterology.

[43]  Zhe Wang,et al.  Gossypol-Induced Differentiation in Human Leukemia HL-60 Cells , 2006, International journal of biomedical science : IJBS.

[44]  Yusuke Nakamura,et al.  PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. , 2006, Cancer research.

[45]  Judith A Ferry,et al.  Burkitt's lymphoma: clinicopathologic features and differential diagnosis. , 2006, The oncologist.

[46]  Y. Abe,et al.  Expression and phosphorylation of TOPK during spermatogenesis , 2005, Development, growth & differentiation.

[47]  Yong-Yeon Cho,et al.  Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. , 2005, Cancer research.

[48]  Y. Abe,et al.  Characterization of a MAPKK-like protein kinase TOPK. , 2004, Biochemical and biophysical research communications.

[49]  J. O’Shea,et al.  Tyrosine 813 Is a Site of JAK2 Autophosphorylation Critical for Activation of JAK2 by SH2-Bβ , 2004, Molecular and Cellular Biology.

[50]  J. Toretsky,et al.  PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. , 2001, Blood cells, molecules & diseases.

[51]  C. Allis,et al.  Signaling to Chromatin through Histone Modifications , 2000, Cell.

[52]  Y. Abe,et al.  Cloning and Expression of a Novel MAPKK-like Protein Kinase, Lymphokine-activated Killer T-cell-originated Protein Kinase, Specifically Expressed in the Testis and Activated Lymphoid Cells* , 2000, The Journal of Biological Chemistry.

[53]  D. Branton,et al.  Characterization of PDZ-binding kinase, a mitotic kinase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  P. Pelicci,et al.  Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase. , 1997, Journal of immunology.

[55]  R. Smith,et al.  Burkitt's lymphoma. , 1986, International journal of pediatric otorhinolaryngology.